Therapeutic implication of concomitant chromosomal aberrations in patients with aggressive B-cell lymphomas

R Marullo, SC Rutherford, JP Leonard, L Cerchietti - Cell Cycle, 2016 - Taylor & Francis
R Marullo, SC Rutherford, JP Leonard, L Cerchietti
Cell Cycle, 2016Taylor & Francis
ABSTRACT A subset of diffuse large B-cell lymphomas (DLBCL) harbors concomitant
rearrangements of MYC, BCL2 and BCL6 and is characterized by clinical aggressiveness
and intrinsic refractoriness to standard chemo-immunotherapy. Commonly identified as
“double or triple hit” lymphomas, these diseases represent a therapeutic challenge to
chemotherapy-based regimens and likely require a more targeted approach. Herein we
summarize the unique biological behavior of double and triple hit lymphomas focusing on …
Abstract
A subset of diffuse large B-cell lymphomas (DLBCL) harbors concomitant rearrangements of MYC, BCL2 and BCL6 and is characterized by clinical aggressiveness and intrinsic refractoriness to standard chemo-immunotherapy. Commonly identified as “double or triple hit” lymphomas, these diseases represent a therapeutic challenge to chemotherapy-based regimens and likely require a more targeted approach. Herein we summarize the unique biological behavior of double and triple hit lymphomas focusing on the coordinated network of pathways that enable cancer cells to tolerate the oncogenic stress imposed by the co-expression of MYC, BCL2 and BCL6. We discuss how these enabling pathways contribute to the chemo-refractoriness of these tumors. We propose to exploit lymphoma cells' addiction to these oncogenic networks to design combinatorial treatments for this aggressive disease based on the modulation of epigenetically-silenced pathways and decreasing expression and activity of these oncogenic drivers.
Taylor & Francis Online